Drugs / ChulaCov19 BNA159
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05231369 | Dec 2022 → Jul 2023 | — | Chulalongkorn University | Unknown | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT05605470 | Jan 2023 → Jul 2024 | COVID-19 | Technovalia, Pty Ltd | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ChulaCov19 BNA159 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05605470 ↗ |
| Known as | ChulaCov19 | “ChulaCov19 BNA159 mRNA vaccine is the lipid nanoparticles (LNPs)-encapsulated mRNA-based ChulaCov19 vaccine” NCT05231369 ↗ |
| Modality | Messenger RNA (mRNA) | “mRNA-based ChulaCov19 vaccine” NCT05231369 ↗ |
| Route | Intramuscular | “Intramuscular injection of the investigational vaccine at the assigned dose” NCT05231369 ↗ |